CD8A and neoplasm: TLC388 plus RT, by enhancing the recruitment of tumor-infiltrating activated dendritic cells, activated CD8+ T cell, NK cells, and effector/memory CD8+ cells, which sensitized the response to anti-PD1 antibodies.